As Vertex positions itself for continued growth, its strategic acquisitions and expanding cloud capabilities underscore its ...

Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Mohit Bansal has given his Buy rating due to a combination of factors including Vertex Pharmaceuticals’ promising position in the acute pain management market. The recent presentation of Phase 3 ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

The big biotech leader's share price of around $475 remains below the $500 threshold for now. Vertex stock briefly topped ...

The stock market surged on Donald Trump's election win, with Tesla and Palantir among hundreds of big winners. Nvidia is among 5 stocks that aren't out of range.

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...

Vertex Pharmaceuticals accounts for 2.8% of Barlow Wealth Partners Inc.’s portfolio, making the stock its 9th largest position. Barlow Wealth Partners Inc.’s holdings in Vertex Pharmaceuticals ...

Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at approximately $25,000. GHP Investment Advisors Inc. acquired a new position in ...

Jupiter Endovascular today announced the first U.S. patient treated in its SPIRARE II U.S. pivotal study for the Vertex ...

The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...